Kenneth Johnson, MD
Hematology & Oncology · Chula Vista, CANPI 1063527711
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (51.1%), speaking fees and gifts — rather than concentrated in one kind of arrangement. 60 manufacturers reported payments, led by BD at 25.2% of the total. Reporting peaked in 2019 at $8,053 and has fallen 78.0% since, to $1,772 in 2025.
Across 505 payments — averaging $36.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- BD$5K
- Novartis$4K
- Merck$832
- AstraZeneca$814
- Pfizer$581
- E.r. Squibb & Sons, L.L.C.$547
- plus $7K from 54 others
Across 80 payments — averaging $12,213 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Beone Medicines Ltd.$192K
- Beigene, Ltd.$173K
- Morphosys AG$164K
- Beone Medicines USA, Inc.$155K
- Incyte Corporation$140K
- AstraZeneca$99K
- plus $55K from 3 others
What the payments were for
- Speaking & faculty fees$4,70025%
- Food & beverage$9,51351%
- Education$1,2127%
- Gifts$1,6889%
- Other$1,5158%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$18,628 in reported general payments places this provider in the 75th percentile of 1,363 hematology & oncology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RevlimidLenalidomide | 47 | $1,003,743 |
| XtandiEnzalutamide | 58 | $773,601 |
| Lenalidomide | 38 | $603,462 |
| PomalystPomalidomide | 22 | $492,555 |
| JakafiRuxolitinib Phosphate | 28 | $483,688 |
| IdhifaEnasidenib Mesylate | 12 | $411,196 |
| TagrissoOsimertinib Mesylate | 19 | $329,016 |
| LonsurfTrifluridine/Tipiracil Hcl | 17 | $319,802 |
| TibsovoIvosidenib | 13 | $286,252 |
| NinlaroIxazomib Citrate | 20 | $274,013 |
| TazverikTazemetostat Hydrobromide | 13 | $267,096 |
| SprycelDasatinib | 12 | $253,553 |
| IbrancePalbociclib | 16 | $244,795 |
| ErleadaApalutamide | 12 | $240,712 |
| PromactaEltrombopag Olamine | 24 | $189,997 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bristol Myers SquibbRevlimid, Idhifa | $170 | $1,414,93959 claims |
| Astellas Pharma US IncXtandi | $268 | $773,60158 claims |
| E.r. Squibb & Sons, L.L.C.Pomalyst, Sprycel | $547 | $746,10834 claims |
| Incyte CorporationJakafi | $124 | $483,68828 claims |
| AstraZenecaTagrisso | $814 | $329,01619 claims |
| Taiho Oncology, Inc.Lonsurf | $109 | $319,80217 claims |
| Servier Pharmaceuticals LLCTibsovo | $25 | $286,25213 claims |
| PfizerIbrance, Eliquis | $581 | $274,49147 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Ninlaro | $218 | $274,01320 claims |
| Ipsen Biopharmaceuticals, IncTazverik | $118 | $267,09613 claims |
| Johnson & JohnsonErleada, Xarelto | $374 | $263,54326 claims |
| NovartisPromacta | $4,138 | $189,99724 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,363 hematology & oncology providers in California.
Other hematology & oncology in Chula Vista
- Dennis SlamonLos Angeles$3.1M
- Sandra HorningStanford$2.5M
- Mohammadbagher ZiariCorona$2.5M
- George YaghmourLos Angeles$1.9M
- Robert VescioWest Hollywood$1.1M
- Kevin KellyLos Angeles$894K
- Johnny ChangEncino$884K
- Nitin RohatgiSacramento$814K
- Omid HamidSanta Monica$809K
- Catherine CoombsOrange$786K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.